Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 593

1.

Hypertensive Heart Failure: Sprinting to the Finish Line to Prevent End-Organ Damage.

Baliga RR, Bossone E, Bakris GL.

Heart Fail Clin. 2019 Oct;15(4):xiii-xv. doi: 10.1016/j.hfc.2019.07.001. No abstract available.

PMID:
31472892
2.

Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting.

Polonsky TS, Bakris GL.

Heart Fail Clin. 2019 Oct;15(4):455-461. doi: 10.1016/j.hfc.2019.06.006. Epub 2019 Jul 20. Review.

PMID:
31472881
3.

Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline.

Rosenzweig JL, Bakris GL, Berglund LF, Hivert MF, Horton ES, Kalyani RR, Murad MH, Vergès BL.

J Clin Endocrinol Metab. 2019 Jul 31. pii: jc.2019-01338. doi: 10.1210/jc.2019-01338. [Epub ahead of print]

PMID:
31365087
4.

Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors.

Bakris GL.

Am J Kidney Dis. 2019 Jun 28. pii: S0272-6386(19)30776-0. doi: 10.1053/j.ajkd.2019.05.009. [Epub ahead of print] No abstract available.

PMID:
31262591
5.

Assessing Wide Pulse Pressure Hypertension: Data Beyond the Guidelines.

Bakris GL, Laffin LJ.

J Am Coll Cardiol. 2019 Jun 11;73(22):2856-2858. doi: 10.1016/j.jacc.2019.03.494. No abstract available.

PMID:
31171091
6.

Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia.

Vijayakumar S, Butler J, Bakris GL.

Eur Heart J Suppl. 2019 Feb;21(Suppl A):A20-A27. doi: 10.1093/eurheartj/suy030. Epub 2019 Feb 26.

7.

Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis.

Sternlicht H, Bakris GL.

Curr Hypertens Rep. 2019 Feb 12;21(2):12. doi: 10.1007/s11906-019-0920-4. Review.

PMID:
30747296
8.

Novel therapies for diabetic kidney disease.

Cherney DZI, Bakris GL.

Kidney Int Suppl (2011). 2018 Jan;8(1):18-25. doi: 10.1016/j.kisu.2017.10.005. Epub 2017 Dec 29. Review.

9.

Update on reducing the development of diabetic kidney disease and cardiovascular death in diabetes.

Bakris GL.

Kidney Int Suppl (2011). 2018 Jan;8(1):1. doi: 10.1016/j.kisu.2017.10.002. Epub 2017 Dec 29. No abstract available.

10.

MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol.

Parati G, Agabiti-Rosei E, Bakris GL, Bilo G, Branzi G, Cecchi F, Chrostowska M, De la Sierra A, Domenech M, Dorobantu M, Faria T, Huo Y, Jelaković B, Kahan T, Konradi A, Laurent S, Li N, Madan K, Mancia G, McManus RJ, Modesti PA, Ochoa JE, Octavio JA, Omboni S, Palatini P, Park JB, Pellegrini D, Perl S, Podoleanu C, Pucci G, Redon J, Renna N, Rhee MY, Rodilla Sala E, Sanchez R, Schmieder R, Soranna D, Stergiou G, Stojanovic M, Tsioufis K, Valsecchi MG, Veglio F, Waisman GD, Wang JG, Wijnmaalen P, Zambon A, Zanchetti A, Zhang Y.

BMJ Open. 2018 Dec 19;8(12):e021038. doi: 10.1136/bmjopen-2017-021038.

11.

Creatinine Bump Following Antihypertensive Therapy.

Bakris GL, Agarwal R.

Hypertension. 2018 Dec;72(6):1274-1276. doi: 10.1161/HYPERTENSIONAHA.118.12051. No abstract available.

PMID:
30571245
12.

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).

Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, Cannon CP, Bakris GL; EXAMINE Investigators.

Am J Cardiol. 2019 Feb 1;123(3):382-391. doi: 10.1016/j.amjcard.2018.10.035. Epub 2018 Nov 6.

PMID:
30477800
13.

Intradialytic Hypotension: Is Midodrine the Answer?

Hammes M, Bakris GL.

Am J Nephrol. 2018;48(5):378-380. doi: 10.1159/000494805. Epub 2018 Nov 13. No abstract available.

14.

Ambulatory Blood Pressure Monitoring.

Polonsky TS, Bakris GL.

JAMA. 2018 Nov 6;320(17):1807-1808. doi: 10.1001/jama.2018.14856. No abstract available.

PMID:
30398582
15.

Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.

White WB, Jalil F, Cushman WC, Bakris GL, Bergenstal R, Heller SR, Liu Y, Mehta C, Zannad F, Cannon CP.

J Am Heart Assoc. 2018 Oct 16;7(20):e009114. doi: 10.1161/JAHA.118.009114.

16.

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council.

Hypertension. 2018 Nov;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084.

17.

Has the Sun Set on Nighttime Dosing in Uncomplicated Hypertension?

Laffin LJ, Bakris GL.

Hypertension. 2018 Oct;72(4):836-838. doi: 10.1161/HYPERTENSIONAHA.118.11207. No abstract available.

18.

Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.

Ferdinand KC, Bakris GL, Cushman WC, Weber MA, Lloyd E, Wu J, White WB.

Am J Cardiol. 2018 Nov 1;122(9):1496-1505. doi: 10.1016/j.amjcard.2018.07.022. Epub 2018 Aug 4.

19.

Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events.

Bakris GL, Polonsky TS.

J Am Coll Cardiol. 2018 Sep 11;72(11):1224-1226. doi: 10.1016/j.jacc.2018.07.016. No abstract available.

20.

Initial single-pill combinations for antihypertensive treatment: greater cardiovascular mortality reduction yet still not used.

Ali WE, Bakris GL.

Eur Heart J. 2018 Oct 21;39(40):3662-3663. doi: 10.1093/eurheartj/ehy500. No abstract available.

PMID:
30137271
21.

Renal denervation: one step backwards, three steps forward.

Schlaich MP, Bakris GL.

Nat Rev Nephrol. 2018 Oct;14(10):602-604. doi: 10.1038/s41581-018-0040-4. No abstract available.

PMID:
29980772
22.

Hyperkalaemia in diabetes: a silent risk predicting poor outcomes.

K Dojki F, Bakris GL.

Diabet Med. 2018 Aug;35(8):1049-1050. doi: 10.1111/dme.13683. No abstract available.

PMID:
29790205
23.

Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial.

Sharma A, Cannon CP, White WB, Liu Y, Bakris GL, Cushman WC, Zannad F.

J Am Heart Assoc. 2018 May 16;7(11). pii: e007649. doi: 10.1161/JAHA.117.007649.

24.

Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN.

Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M, Mayo MR, Garza D, Zawadzki R, Berman L, Bushinsky DA.

ESC Heart Fail. 2018 Aug;5(4):592-602. doi: 10.1002/ehf2.12292. Epub 2018 May 16.

25.

Hypertension.

Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, Grassi G, Jordan J, Poulter NR, Rodgers A, Whelton PK.

Nat Rev Dis Primers. 2018 Mar 22;4:18014. doi: 10.1038/nrdp.2018.14. Review.

26.

Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes.

de Boer IH, Bakris GL.

Diabetes Care. 2018 Apr;41(4):662-663. doi: 10.2337/dci17-0053. No abstract available.

27.

Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Sattar N, McGuire DK, Januzzi JL, Stockbridge N, Butler J.

J Am Coll Cardiol. 2018 Mar 27;71(12):1379-1390. doi: 10.1016/j.jacc.2018.01.047. Epub 2018 Mar 10. Review.

28.

Blood pressure reduced to new guideline goals in patients with high-normal glucose further reduces cardiovascular events.

Al Dhaybi O, Bakris GL.

J Clin Hypertens (Greenwich). 2018 Apr;20(4):625-626. doi: 10.1111/jch.13242. Epub 2018 Mar 13. No abstract available.

29.

Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.

Bakris GL, Zhao L, Kupfer S, Juhasz A, Hisada M, Lloyd E, Oparil S.

J Clin Hypertens (Greenwich). 2018 Apr;20(4):694-702. doi: 10.1111/jch.13230. Epub 2018 Mar 4.

30.

Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.

Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lozada LG, Stahl E, Weiner DE, Chertow GM.

Am J Kidney Dis. 2018 Jun;71(6):851-865. doi: 10.1053/j.ajkd.2017.12.009. Epub 2018 Feb 27. Review.

PMID:
29496260
31.

Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not.

Bakris GL, Molitch M.

Diabetes Care. 2018 Mar;41(3):389-390. doi: 10.2337/dci17-0047. No abstract available.

PMID:
29463664
32.

Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes.

Laffin LJ, Bakris GL.

Diabetes Obes Metab. 2018 Jun;20(6):1335-1336. doi: 10.1111/dom.13249. Epub 2018 Feb 28. No abstract available.

33.

Blood Pressure Control and Cardiovascular/Renal Outcomes.

Dojki FK, Bakris GL.

Endocrinol Metab Clin North Am. 2018 Mar;47(1):175-184. doi: 10.1016/j.ecl.2017.10.008. Review.

PMID:
29407050
34.

Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.

Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ.

Am J Nephrol. 2018;47(1):40-47. doi: 10.1159/000486398. Epub 2018 Jan 18.

35.

SGLT2 Inhibitors and Mechanisms of Hypertension.

Briasoulis A, Al Dhaybi O, Bakris GL.

Curr Cardiol Rep. 2018 Jan 19;20(1):1. doi: 10.1007/s11886-018-0943-5. Review.

PMID:
29349558
36.

Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.

Garlo KG, White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DM.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):398-405. doi: 10.2215/CJN.05280517. Epub 2018 Jan 16.

37.

A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.

Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S.

J Hypertens. 2018 Apr;36(4):947-956. doi: 10.1097/HJH.0000000000001647.

38.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

39.

Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.

Weir MR, Bushinsky DA, Benton WW, Woods SD, Mayo MR, Arthur SP, Pitt B, Bakris GL.

Am J Med. 2018 May;131(5):555-564.e3. doi: 10.1016/j.amjmed.2017.11.011. Epub 2017 Nov 26.

40.

Initial Single-Pill Blood Pressure-Lowering Therapy: Should It Be for Most People?

Al Dhabyi O, Bakris GL.

J Am Heart Assoc. 2017 Nov 18;6(11). pii: e007760. doi: 10.1161/JAHA.117.007760. No abstract available.

41.

Consequences of Overinterpreting Serum Creatinine Increases when Achieving BP Reduction: Balancing Risks and Benefits of BP Reduction in Hypertension.

Yamout H, Bakris GL.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):9-10. doi: 10.2215/CJN.11811017. Epub 2017 Nov 3. No abstract available.

42.

High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.

Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB.

Diabetes Obes Metab. 2018 Mar;20(3):654-659. doi: 10.1111/dom.13136. Epub 2017 Nov 21.

43.

MY APPROACH to the elderly patient with resistant hypertension.

Bakris GL.

Trends Cardiovasc Med. 2018 Jan;28(1):79-80. doi: 10.1016/j.tcm.2017.09.008. Epub 2017 Oct 3. No abstract available.

PMID:
29032932
44.

High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3.

Waksman R, Bakris GL, Steinvil A, Garcia-Garcia H, Brown AL, DiFilippo W, Scott T, Singh J, DeBruin V, Jones D, Jolivette D, Bhatt DL.

Am Heart J. 2017 Oct;192:76-84. doi: 10.1016/j.ahj.2017.06.011. Epub 2017 Jun 27.

PMID:
28938966
45.

Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist.

Laffin LJ, Jafar MS, Bakris GL.

J Clin Hypertens (Greenwich). 2017 Nov;19(11):1202-1203. doi: 10.1111/jch.13052. Epub 2017 Jun 23.

46.

Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease.

Ai Dhaybi O, Bakris GL.

Clin Pharmacol Ther. 2017 Sep;102(3):450-458. doi: 10.1002/cpt.758. Epub 2017 Jul 21. Review.

PMID:
28589612
47.

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension.

Johnson W, White WB, Sica D, Bakris GL, Weber MA, Handley A, Perez A, Cao C, Kupfer S, Saunders EB.

J Clin Hypertens (Greenwich). 2017 Jul;19(7):695-701. doi: 10.1111/jch.12993. Epub 2017 May 11.

48.

Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations.

Kario K, Bhatt DL, Brar S, Bakris GL.

Circ J. 2017 Aug 25;81(9):1337-1345. doi: 10.1253/circj.CJ-16-1237. Epub 2017 Apr 29.

49.

Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up.

de Leeuw PW, Bisognano JD, Bakris GL, Nadim MK, Haller H, Kroon AA; DEBuT-HT and Rheos Trial Investigators.

Hypertension. 2017 May;69(5):836-843. doi: 10.1161/HYPERTENSIONAHA.117.09086. Epub 2017 Mar 20.

PMID:
28320856
50.

Resistant Hypertension: A Refractory Disease or Refractory Patient.

Sternlicht H, Bakris GL.

Hypertension. 2017 Apr;69(4):582-583. doi: 10.1161/HYPERTENSIONAHA.117.08924. No abstract available.

PMID:
28264919

Supplemental Content

Loading ...
Support Center